CXCL16 treatment accelerated the death of mice with secondary transplantation of BCR-ABLtTA cells, indicating that CXCL16 promotes the progression of Ph+ B-ALL (Fig. 7h). This evidence concerns the gene BCR and acute lymphoblastic leukemia.